SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Data Sheet (Cat.No.T6106)

TargetMol

Selinexor (KPT-330)

Chemical Properties



CAS No. : 1393477-72-9

Formula: C17H11F6N7O

Molecular Weight: 443.31

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Selinexor (KPT-330) is a small molecule inhibitor of CRM1 with selective and oral activity. Selinexor blocks the cell cycle, induces apoptosis, and has antitumor activity for the treatment of multiple myeloma.
Targets(IC50)	CRM1
In vitro	**METHODS**: Six T-ALL cells, MOLT-4, Jurkat, HBP-ALL, KOPTK-1, SKW-3 and DND-41, were treated with Selinexor (0-1000 μM) for 72 h. Cell growth inhibition was detected using Cell Titer Glo assay. **RESULTS**: Selinexor treatment inhibited T-ALL cell growth with IC50 values of 34-203 nM. [1] **METHODS**: Multiple myeloma cells MM1S were treated with Selinexor (100 nM) for 8 h. The expression levels of target proteins were detected by Western Blot. **RESULTS**: Selinexor treatment resulted in the accumulation of p53, IκB, p21 and p27 in the nucleus of MM1S cells. [2]
In vivo	**METHODS**: To assay antitumor activity in vivo, Selinexor (20-25 mg/kg) was administered by gavage to NSG mice harboring the human T-ALL tumor MOLT-4 three times per week for thirty-six days. **RESULTS**: Selinexor-treated mice exhibited significant inhibition of leukemia cell growth with significant survival benefit. [1] **METHODS**: To assay anti-tumor activity in vivo, Selinexor (20 mg/kg) was administered by gavage three times per week for four weeks to an NSG mouse model of primary AML in patients. **RESULTS**: Selinexor was cytotoxic to primary AML cells transplanted into mice. [3]

Solubility Information

Solubility	H2O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: 38 mg/mL (85.7 mM), DMSO: 55 mg/mL (124.07 mM), (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2558 mL	11.2788 mL	22.5576 mL
5 mM	0.4512 mL	2.2558 mL	4.5115 mL
10 mM	0.2256 mL	1.1279 mL	2.2558 mL
50 mM	0.0451 mL	0.2256 mL	0.4512 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Han Y, Hu A, Qu Y, et al.Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia.Pharmacological Research.2023: 106700.